The research and development (R&D) landscape for glucagon-like peptide-1 (GLP-1) receptor agonists and metabolic therapies is evolving beyond initial indications for treating glycemia in type 2 diabetes and weight reduction in obese/overweight with co-morbidities. Additional indications now include metabolic dysfunction-associated steatohepatitis (MASH), major adverse cardiovascular events (MACE) reduction, delay of renal disease progression, and treatment…